Regorafenib is intended to treat patients with metastatic colorectal cancer whose disease has progressed after standard therapy.
FDA grants priority review to medicines that provide a treatment where little or no adequate therapy exists. FDA completes a priority review within six months of receiving the new drug application rather than the standard 10-month review cycle.
The application for regorafenib was filed at the end of April.
Related Articles on Colon Cancer:
Study: CT Colonography Effective Screening Tool for Colon Cancer
